Medullary thyroid cancer;Le cancer medullaire de la thyroide

Revue du Praticien

Volumn 46, Issue 19, 1996, Pages 2303-2308

  Modigliani, Élisabeth ^a,b  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN;

CALCITONIN BLOOD LEVEL; FAMILIAL CANCER; HUMAN; MUTATION; SHORT SURVEY; THYROID MEDULLARY CARCINOMA; GENETICS; MEDULLARY CARCINOMA; PROGNOSIS; REVIEW; RISK FACTOR; THYROID TUMOR;

CARCINOMA, MEDULLARY; HUMANS; PROGNOSIS; RISK FACTORS; THYROID NEOPLASMS;

EID: 0029840265     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (23)

1. Calmettes C. Le cancer médullaire de la thyroïde: acquis et interrogations. Médecine Science 1991; 7: 22-9.
2. Howe JR, Norton JA, Wells SA et al. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A. Surgery 1993; 114 (6): 1070-7.
3. Kraimps JL, Denizot A, Carnaille B et al. Primary hyperparathyroidism in MEN type 2A: a retrospective French multicentric study on 56 cases by the GETC. Word J Surg 1996; 20: 808-13.
4. Casanova S, Rosenberg-Bourgin M, Farkas D et al. Pheochromocytoma in multiple endocrine neoplasia type 2A: survey of 100 cases. Clin Endocrinol (Oxf) 1993; 38: 531-7.
5. Modigliani E, Vasen HFA, Raue K et al. Pheochromocytoma in multiple endocrine neoplasia type 2. European study. J Intern Med 1995; 238: 363-7.
6. Robinson MF, Fust FJ, Nunziata V et al. Characterization of the clinical features of five families with hereditary primary cutaneous lichen amyloidosis and multiple endocrine neoplasia type 2. Henry Ford Hosp Med J 1992; 40: 249-50.
7. Vasen HPA, Van Der Feltz M, Raue F et al. The natural course of multiple endocrine neoplasia type 2B: a study of 18 cases. Arch Intern Med 1992; 152: 1250-2.
8. Mulligan L, Kwok JBJ, Healey CS et al. Germ-line mutations of the Ret proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-60.
9. Schuffenecker I, Billaud M, Calender A et al. and the GETC. Ret proto-oneogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994; 3: 1939-43.
10. Niccoli P, Conte-Devolx B, Lejeune PJ et al. Les hypercalcitoninémies en dehors des cancers médullaires du corps thyroïde. Ann Endocrinol 1996; 57: 15-22.
11. Franc B. Le cancer médullaire de la thyroïde: la place de l'anatomie pathologique face aux tests génétiques. Rev Fr Lab 1994; 270: 27-36.
12. Barbot N, Schuffenecker I, Calmettes C et al. Conditions actuelles du dépistage du carcinome médullaire du corps thyroïde. Rev Fr Endocrinol Clin 1993; 34: 539-48.
13. Lips C, Landsvater RM, Hoppener et al. Clinical screening as compared with DNA analysis in families with multiple endocrine noplasia type 2A. N Engl J Med 1994; 331: 828-35.
14. Wells SA, Donis-Keller H. Current perspectives on the diagnosis and management of patients with multiple endocrine neoplasia type 2 syndromes. Endocrinol Metab Clin North Am 1994; 23: 215-29.
15. Proye C, Marmousez T. Cancer médullaire de la thyroïde: Moyens thérapeutiques, chirurgie de première intention. In: Calmettes C, Guliana JM (eds). Medullary Thyroid carcinoma. John Libbey Eurotext Ltd, 1991; 211: 199-205.
16. Proye C, Marmousez T, Modigliani E et al. Strategie diagnostique et conduite à tenir dans les hypercalcitoninémies résiduelles après traitement chirurgical du cancer médullaire de la thyroïde. Rev Fr Endocrinol Clin 1993; 34: 549-62.
17. Schlumberger M, Abdelmoumene N, Delisle MJ et al. and the GETC. Treatment of advanced medullary thyroid cancer. Br J Cancer 1995; 71: 363-5.
18. Modigliani E, Cohen E, Franc B et al. Les facteurs pronostiques du cancer médullaire de la thyroïde. Rev Fr Endocrinol Clin 1995; 36: 405-15.
19. Raue F, Kotzerke J, Reinwein D et al. Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German medullary thyroid carcinoma register. Clin Invest Med 1993; 71: 7-12.
20. Saad M, Ordonez N, Rashid R et al. Medullary carcinoma of the thyroid: a study of the clinical features and pronostic factors in 161 patients. Medicine 1984; 63: 319-36.
21. Frank-Raue K, Bihl H, Dörr U et al. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol 1995; 42: 31-7.
22. Peltier F, Curtet C, Chatal JF et al. Radioimmunodetection of MCT using a bispecific anti-CEA/anti-indium DTPA antibody and an indium-labelled DTPA dimer. Nuci Med 1993; 34: 1267-73.
23. Abdelmoumene N, Schiumberger M, Gardet P et al. Selective venous sampling catheterisation for localization of persisting medullary thyroid carcinoma. Br J Cancer 1994; 69 (6): 1141-4.